Press Releases

All Releases
View Summary Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398
Apr 8, 2014
PDF 21.2 KB Add to Briefcase
View Summary Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting
Mar 31, 2014
PDF 18.4 KB Add to Briefcase
View Summary Merrimack Provides Fourth Quarter and Full Year 2013 Financial Results
Feb 27, 2014
PDF 24.9 KB Add to Briefcase
View Summary Merrimack to Present at the Cowen and Company 34th Annual Health Care Conference
Feb 24, 2014
PDF 13.7 KB Add to Briefcase
View Summary Merrimack Announces Timing of Fourth Quarter 2013 Investor Conference Call
Feb 20, 2014
PDF 14.6 KB Add to Briefcase
View Summary Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics
Feb 18, 2014
PDF 17.7 KB Add to Briefcase
View Summary Merrimack Initiates Phase 1 Clinical Study of MM-398 in Combination With Cyclophosphamide for Pediatric Solid Tumors
Jan 23, 2014
PDF 20.2 KB Add to Briefcase
View Summary Merrimack to Present Preclinical Data at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium
Jan 13, 2014
PDF 16.7 KB Add to Briefcase
View Summary Merrimack to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Dec 20, 2013
PDF 13.6 KB Add to Briefcase
View Summary Merrimack Announces Encouraging Clinical Data From Expanded Phase 1 Study of MM-302 for the Treatment of Advanced HER2-Positive Breast Cancer
Dec 13, 2013
PDF 16.2 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present Phase 1 Data on MM-302 in Patients With Advanced HER2-Positive Breast Cancer
Dec 6, 2013
PDF 11.7 KB Add to Briefcase
View Summary Merrimack to Present at the Oppenheimer 24th Annual Healthcare Conference
Dec 4, 2013
PDF 9.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals' MM-121 Demonstrates Positive Signal in Two Phase 2 ER/PR+ Breast Cancer Studies
Nov 26, 2013
PDF 17.3 KB Add to Briefcase
View Summary Merrimack and Actavis Announce Nanotechnology Collaboration
Nov 26, 2013
PDF 15.6 KB Add to Briefcase
View Summary Merrimack Provides Third Quarter 2013 Operating Update and Financial Results
Nov 7, 2013
PDF 23.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Updates Timing of Third Quarter 2013 Investor Conference Call
Nov 5, 2013
PDF 10.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
Oct 30, 2013
PDF 12.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Third Quarter 2013 Investor Conference Call
Oct 29, 2013
PDF 10.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present Preclinical Data at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 15, 2013
PDF 11.4 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Completes Enrollment of Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer
Oct 1, 2013
PDF 12.4 KB Add to Briefcase
Showing 1-20 of 117 Page: 1 2 3 4 5 6  Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ: MACK)

Price:
4.52

Change:
+ 0.02

Day High:
4.65

Day Low:
4.41

Volume:
722,400

4:00 PM ET on Apr 17, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools